EGFR and nasopharyngeal carcinoma: Targeted therapies for NPC have shown promise by focusing on specific molecular pathways and genetic aberrations driving NPC progression, including EGFR inhibitors (cetuximab) and immune checkpoint inhibitors (pembrolizumab and nivolumab) [1, 5, 8].